Mirvetuximab soravtansine · Elahere

Antibody–drug conjugate

Also known as IMGN853, TAK-853

Approved / Phase 4Mechanism not established
Approvedregulatory verdict

Evidence outlook

Approved: Ovarian Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (5)
Ovarian Cancer
NCT05445778 · AbbVie
2023-03-15 – 2032-05 · Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
What this study did
NCT05622890 · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
2022-08-18 – 2023-12-31 · Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
What this study did
NCT04296890 · ImmunoGen, Inc.
2020-07-23 – 2022-11-16 · Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
What this study did
NCT02631876 · ImmunoGen, Inc.
2016-03-02 – 2020-01 · Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Ovarian Cancer
What this study did
Phase 2 (16)
Ovarian Cancer
NCT07934121 · Tongji Hospital
2026-11-10 – 2028-06-30 · Platinum-Sensitive Recurrent Ovarian Cancer
What this study did
NCT04606914 · University of Alabama at Birmingham
2021-05-27 – 2028-05-31 · Ovarian Cancer, Fallopian Tube, Primary Peritoneal Cancer
What this study did
NCT07741630 · Peking University Third Hospital
2026-08-15 – 2028-04-30 · PROC
What this study did
NCT06365853 · AbbVie
2024-07-29 – 2027-02 · Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive
What this study did
NCT04274426 · AGO Research GmbH
2021-10-13 – 2026-12 · Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
What this study did
NCT05456685 · AbbVie
2022-09-28 – 2026-11 · High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
What this study did
NCT05041257 · AbbVie
2021-10-19 – 2024-12-12 · Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
What this study did
Other / comorbidity
NCT05887609 · University of Colorado, Denver
2023-10-03 – 2031-01-31 · Ovary Cancer, Peritoneal Cancer, Fallopian Tube Cancer
What this study did
NCT07825753 · Fudan University
2026-09-10 – 2030-02-01 · Advanced or Metastatic Pancreatic Adenocarcinoma, Advanced or Metastatic Breast Cancer (BC)
What this study did
NCT03832361 · Alessandro Santin
2020-07-15 – 2028-10 · Endometrial Cancer
What this study did
NCT03835819 · Dana-Farber Cancer Institute
2020-01-02 – 2027-02-01 · Endometrial Cancer
What this study did
NCT03836157 · University of Oklahoma
2019-05-31 – 2022-05 · Endometrial Cancer, Endometrial Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma
What this study did
NCT03106077 · M.D. Anderson Cancer Center
2017-06-05 – 2019-10-01 · Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Negative, Folate Receptor Alpha Positive, HER2/Neu Negative, Progesterone Receptor Negative, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
What this study did
Phase 1/2 (2)
Ovarian Cancer
NCT06390995 · Takeda
2024-05-20 – 2027-03-19 · Ovarian Cancer, Solid Tumors
What this study did
Phase 1 (5)
Ovarian Cancer
NCT06840886 · Pheast Therapeutics
2025-03-31 – 2031-04 · Advanced Solid Tumors, Ovarian Cancer, Endometrial Cancer, Cholangiocarcinoma, CNS Tumor, Breast Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Carcinosarcoma, Ovarian
What this study did
NCT03552471 · Ohio State University Comprehensive Cancer Center
2018-07-12 – 2022-12-19 · BRCA1 Gene Mutation, BRCA2 Gene Mutation, Folate Receptor Alpha Positive, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Recurrent Uterine Serous Carcinoma, Recurrent Uterine Carcinosarcoma, Platinum Resistant Ovarian Cancer
What this study did
Other / comorbidity
NCT02996825 · City of Hope Medical Center
2017-10-02 – 2024-02-09 · Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Triple-Negative Breast Carcinoma
What this study did
NCT03045393 · Duke University
2017-04-17 – 2018-02-28 · Breast Cancer Triple Negative
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
Ovarian Cancer
NCT07218809 · AstraZeneca
2025-12-29 – 2029-12-27 · Epithelial Ovarian Cancer
What this study did

Competitive landscape

This drug's own stage for Ovarian Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Mirvetuximab Soravtansine (Elahere): this drugApprovedAntibody–drug conjugate—not yet gradedNo reviewed efficacy summary in this indication
Avutometinib / Defactinib (Avmapki Fakzynja Co-Pack)ApprovedSmall moleculeMEK1/2 and RAF (CRAF, BRAF), FAKnot yet gradedNo reviewed efficacy summary in this indication
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor Inhibitornot yet gradedNo reviewed efficacy summary in this indication
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)not yet gradedNo reviewed efficacy summary in this indication
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
NiraparibApprovedSmall moleculePARP1/2Reliable signal
NCT02655016: Progression Free Survival (Up to 34 months): Placebo 8.2 Months (95% CI 7.3 to 8.5) | Niraparib 13.8 Months (95% CI 11.5 to 14.9)
OlaparibApprovedSmall moleculePARPnot yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Reliable signalNo reviewed efficacy summary in this indication
Relacorilant (Lifyorli)ApprovedSmall moleculeGlucocorticoid receptorPartial signalNo reviewed efficacy summary in this indication
RucaparibApprovedSmall moleculePARP (poly ADP-ribose polymerase) enzymes, PARP1/2Reliable signalFeatured results are non-efficacy only in this race
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
DurvalumabPhase 3Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
GSK 5733584Phase 3——not yet gradedNo reviewed efficacy summary in this indication
INCB123667Phase 3Small moleculeCDK2not yet gradedNo reviewed efficacy summary in this indication
Izalontamab BrengitecanPhase 3Antibody–drug conjugateEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
Olvimulogene NanivacirepvecPhase 3Oncolytic virusNo discrete molecular targetnot yet gradedNo reviewed efficacy summary in this indication
Raludotatug DeruxtecanPhase 3Antibody–drug conjugateCDH6 (Cadherin-6)not yet gradedNo reviewed efficacy summary in this indication
Rinatabart Sesutecan (Rina-S)Phase 3Antibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
Sofetabart MipitecanPhase 3Antibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication
Torvutatug SamrotecanPhase 3Antibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab BrengitecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
BirinapantPhase 2—IAP (inhibitor of apoptosis) proteinsnot yet gradedNo reviewed efficacy summary in this indication
Ixotatug VedotinPhase 2Antibody–drug conjugateClaudin 6 (CLDN6)not yet gradedNo reviewed efficacy summary in this indication
StenoparibPhase 2Small moleculePARP1/2, Tankyrase 1/2not yet gradedNo reviewed efficacy summary in this indication
COM701Phase 1/2Monoclonal antibodyPVRIG (CD112R)not yet gradedNo reviewed efficacy summary in this indication
REGN5668Phase 1/2Multispecific antibodyMUC16 x CD28not yet gradedNo reviewed efficacy summary in this indication
RezatapoptPhase 1/2Small moleculep53 reactivatornot yet gradedNo reviewed efficacy summary in this indication
TUB-040Phase 1/2Antibody–drug conjugateNaPi2b (sodium-dependent phosphate transporter, SLC34A2)not yet gradedNo reviewed efficacy summary in this indication
UbamatamabPhase 1/2Monoclonal antibodyMUC16 x CD3not yet gradedNo reviewed efficacy summary in this indication
27T51Phase 1Cell therapyMUC16not yet gradedNo reviewed efficacy summary in this indication
ABBV-901Phase 1UndisclosedFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication
APG-2449Phase 1Small moleculeFAK / ALK / ROS1not yet gradedNo reviewed efficacy summary in this indication
CRX100Phase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication
IDE-161Phase 1Small moleculePARGnot yet gradedNo reviewed efficacy summary in this indication
XmAb541Phase 1Multispecific antibodyClaudin 6 (CLDN6) x CD3not yet gradedNo reviewed efficacy summary in this indication
Luveltamab TazevibulinDiscontinuedAntibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(11 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Elahere (Mirvetuximab soravtansine) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
November 2026 (1)
Phase 2Ovarian CancerActive not recruiting
Est. primary completion 2026-11 · NCT05456685 · CT.gov ↗
What to watch
2027 (5)
February 2027 (1)
Phase 2Ovarian CancerActive not recruiting
Est. primary completion 2027-02 · NCT06365853 · CT.gov ↗
What to watch
April 2027 (1)
Phase 3Ovarian CancerActive not recruiting
Est. primary completion 2027-04 · NCT05445778 · CT.gov ↗
What to watch
June 2027 (1)
Phase 2Ovarian CancerNot yet recruiting
Est. primary completion 2027-06-30 · NCT07741630 · CT.gov ↗
What to watch
July 2027 (1)
Phase 2Ovarian CancerRecruiting
Est. primary completion 2027-07 · NCT04606914 · CT.gov ↗
What to watch
September 2027 (1)
Phase 2Advanced or Metastatic Pancreatic Adenocarcinoma, Advanced or Metastatic Breast Cancer (BC)Not yet recruiting
Est. primary completion 2027-09-01 · NCT07825753 · CT.gov ↗
What to watch
2028 (1)
June 2028 (1)
Phase 2Ovarian CancerNot yet recruiting
Est. primary completion 2028-06-30 · NCT07934121 · CT.gov ↗
What to watch
2029 (3)
January 2029 (2)
Phase 2Ovarian CancerRecruiting
Est. primary completion 2029-01 · NCT07059845 · CT.gov ↗
What to watch
Phase 2Ovary Cancer, Peritoneal Cancer, Fallopian Tube CancerRecruiting
Est. primary completion 2029-01-31 · NCT05887609 · CT.gov ↗
What to watch
April 2029 (1)
Phase 1Ovarian CancerRecruiting
Est. primary completion 2029-04 · NCT06840886 · CT.gov ↗
What to watch
2030 (1)
February 2030 (1)
Phase 2Ovarian CancerRecruiting
Est. primary completion 2030-02 · NCT06890338 · CT.gov ↗
What to watch

See the full readout calendar ↗